The Motley Fool··James HalleyTelix Pharmaceuticals Eyes Growth With Nuclear Medicine Expansion
Telix Pharmaceuticals expands its nuclear medicine presence with approved cancer-targeting drugs and 56% revenue growth, positioning itself as a key player in oncology diagnostics and therapeutics.
TLXbiotechradiopharmaceuticals